Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Insider Sells $125,928.31 in Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) insider Terrie Curran sold 19,109 shares of Phathom Pharmaceuticals stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $6.59, for a total value of $125,928.31. Following the sale, the insider now directly owns 360,465 shares in the company, valued at approximately $2,375,464.35. The trade was a 5.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Phathom Pharmaceuticals Trading Down 3.8 %

Shares of NASDAQ:PHAT opened at $6.90 on Friday. The stock has a fifty day simple moving average of $8.00 and a two-hundred day simple moving average of $12.47. Phathom Pharmaceuticals, Inc. has a 12-month low of $6.07 and a 12-month high of $19.71. The stock has a market capitalization of $471.80 million, a price-to-earnings ratio of -1.21 and a beta of 0.56.

Phathom Pharmaceuticals (NASDAQ:PHAT) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($1.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.57) by $0.25. The company had revenue of $16.35 million during the quarter, compared to analysts’ expectations of $12.54 million. During the same period in the prior year, the firm earned ($0.76) EPS. As a group, equities research analysts predict that Phathom Pharmaceuticals, Inc. will post -4.74 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Huntington National Bank raised its holdings in Phathom Pharmaceuticals by 62.2% in the 3rd quarter. Huntington National Bank now owns 1,471 shares of the company’s stock worth $27,000 after acquiring an additional 564 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Phathom Pharmaceuticals by 41.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,470 shares of the company’s stock worth $43,000 after purchasing an additional 722 shares in the last quarter. US Bancorp DE raised its stake in shares of Phathom Pharmaceuticals by 28.6% in the third quarter. US Bancorp DE now owns 5,248 shares of the company’s stock worth $95,000 after purchasing an additional 1,166 shares during the last quarter. Quest Partners LLC bought a new position in shares of Phathom Pharmaceuticals during the third quarter valued at $197,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Phathom Pharmaceuticals during the third quarter valued at $207,000. Institutional investors own 99.01% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on PHAT shares. HC Wainwright restated a “buy” rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a research note on Thursday, December 12th. Needham & Company LLC reissued a “buy” rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research report on Friday, January 10th.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.